a76df2f9_docrine_Cancer_Research___CFCF__Status
[Title] A Phase I, Multi-center, Open-label, Dose Escalation Study of Pasireotide (SOM230) LAR in Patients With Advanced Neuroendocrine Tumors (NETs) [Phase] I [Conditions] Neuroendocrine Tumor [State] CA FL MA TX [Status] 
Enrolling
N o t R e c r u i t i n g
E n r o l l i n g
Clinical Trials Finder | Carcinoid and Pancreatic Neuroendocrine Cancer Research | CFCF
Status